This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

West And Vetter Collaborate To Offer Customers An Innovative Filling Solution For Biopharmaceutical Drugs

Stocks in this article: WST

West (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, and Vetter, a leading international independent specialist in the aseptic filling of drug-delivery systems, have collaborated to provide customers with the ability to source filled Daikyo Crystal Zenith® syringes.

Providing the best solution to the challenges of packaging and delivering today’s sensitive and complex biopharmaceutical products requires not only a unique syringe system, but also the assurance that this system can be filled, handled, validated and approved in accordance with appropriate cGMPs and pharmaceutical practices.

To help customers transition to the Daikyo Crystal Zenith syringe system, West has been working extensively with Vetter. This relationship has allowed both companies to develop and optimize the manufacturing, validation and packaging of the syringe system to engineer compatibility with the filling capabilities and requirements at Vetter. Media fills and equipment validation are underway for the 1mL long insert needle syringe system.

To support this initiative, investments have been made at Vetter’s facilities in Germany and at their new Chicago facility. Capabilities will initially exist for early-phase clinical filling in Germany. Options for commercial-scale filling will be available.

“We are delighted to have the opportunity to offer our customers an innovative solution, combining the benefits of the Daikyo Crystal Zenith syringe system with the biopharmaceutical fill and finish capabilities of one of the world’s leading contract development and manufacturing organizations,” said Donald E. Morel, Jr., Ph.D., West’s Chairman and CEO. “Vetter is an established market leader in the manufacture of aseptically prefilled drug-delivery systems for biopharmaceutical products, and we are pleased to have this ongoing relationship.”

“We’re pleased to partner with West on this advanced new technology,” said Mr. Thomas Otto, Vetter Managing Director. “Vetter has always sought to stay at the forefront of innovation, so that we can serve the needs of our customers and the growing biotechnology industry.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs